Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Spruce Biosciences to Participate in the Jefferies Healthcare Conference By: Spruce Biosciences, Inc. via Business Wire May 24, 2023 at 16:05 PM EDT Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 9, 2023, at 9:30 a.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube. View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005174/en/Contacts Media Contact Will Zasadny Evoke Canale (619) 961-8848 will.zasadny@evokecanale.com media@sprucebio.com Investors Xuan Yang Solebury Strategic Communications (415) 971-9412 xyang@soleburystrat.com investors@sprucebio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Spruce Biosciences to Participate in the Jefferies Healthcare Conference By: Spruce Biosciences, Inc. via Business Wire May 24, 2023 at 16:05 PM EDT Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 9, 2023, at 9:30 a.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube. View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005174/en/Contacts Media Contact Will Zasadny Evoke Canale (619) 961-8848 will.zasadny@evokecanale.com media@sprucebio.com Investors Xuan Yang Solebury Strategic Communications (415) 971-9412 xyang@soleburystrat.com investors@sprucebio.com
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 9, 2023, at 9:30 a.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube. View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005174/en/
Media Contact Will Zasadny Evoke Canale (619) 961-8848 will.zasadny@evokecanale.com media@sprucebio.com Investors Xuan Yang Solebury Strategic Communications (415) 971-9412 xyang@soleburystrat.com investors@sprucebio.com